Eidos Therapeutics (NASDAQ:EIDX) Announces Earnings Results

Eidos Therapeutics (NASDAQ:EIDX) announced its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.01), Bloomberg Earnings reports.

Shares of EIDX stock traded down $2.33 during trading hours on Friday, hitting $32.40. 149,505 shares of the company’s stock were exchanged, compared to its average volume of 145,560. The company has a 50-day moving average price of $33.91. The company has a current ratio of 19.04, a quick ratio of 19.04 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.19 billion and a PE ratio of -17.42. Eidos Therapeutics has a 52 week low of $8.89 and a 52 week high of $41.35.

In other Eidos Therapeutics news, major shareholder Bridgebio Pharma, Inc. bought 1,103,848 shares of the firm’s stock in a transaction dated Friday, May 24th. The shares were bought at an average price of $25.93 per share, for a total transaction of $28,622,778.64. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Uma Sinha sold 5,000 shares of the stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $27.28, for a total value of $136,400.00. The disclosure for this sale can be found here. Insiders have sold 62,000 shares of company stock worth $2,103,590 in the last 90 days. Company insiders own 70.10% of the company’s stock.

A number of brokerages have weighed in on EIDX. Zacks Investment Research upgraded Eidos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 23rd. BTIG Research began coverage on Eidos Therapeutics in a research report on Wednesday, April 17th. They issued a “buy” rating and a $38.00 price target on the stock. Piper Jaffray Companies began coverage on Eidos Therapeutics in a research report on Monday, July 22nd. They issued an “overweight” rating and a $55.00 price target on the stock. Finally, BMO Capital Markets upped their price target on Eidos Therapeutics to $50.00 and gave the company an “outperform” rating in a research report on Monday, July 22nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $35.00.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Further Reading: How is the discount rate different from the Federal Funds rate?

Earnings History for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.